Lactobacillus casei rhamnosus (Lcr35) ( DrugBank: Lactobacillus casei )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 296 | Biliary atresia | 1 |
296. Biliary atresia
Clinical trials : 71 / Drugs : 70 - (DrugBank : 39) / Drug target genes : 35 - Drug target pathways : 60
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00166868 (ClinicalTrials.gov) | December 2003 | 12/9/2005 | Use of Probiotics to Prevent Cholangitis in Children With Biliary Atresia After the Kasai Portoenterostomy | Use of Probiotics to Prevent Cholangitis in Children With Biliary Atresia | Biliary Atresia | Drug: Lactobacillus casei rhamnosus (Lcr35);Drug: Neomycin | National Taiwan University Hospital | NULL | Completed | 4 Months | 3 Years | Both | 30 | N/A | Taiwan |